Hypoparathyroidism (HP)


Hypoparathyroidism is a disease characterized by absence or inappropriately low concentrations of circulating parathyroid hormone (PTH), leading to hypocalcaemia, hyperphosphataemia and elevated fractional excretion of calcium in the urine, with an estimated prevalence of 23 to 37 cases per 100,000 person-years. The most common cause of the disease is anterior neck surgery, followed by genetic, idiopathic and autoimmune aetiologies1-4 .


Conventional treatment includes activated vitamin D and/or calcium supplements, but this treatment does not fully replace the functions of PTH and can lead to short-term problems (such as hypocalcaemia, hypercalcaemia and increased urinary calcium excretion) and long-term complications (such as nephrocalcinosis, kidney stones, renal insufficiency, and brain calcifications), which also have a serious impact on quality of life 1-8 .

MetInfo enterprise content manager system | MetInfo CMS

PTH replacement has emerged as a new treatment option for HP 4.


Reference

1.《Chinese journal of osteoporosis and bone mineral salt diseases》2018;11(4):323-337.

2. Bollerslev J, et al. Eur J Endocrinol. 2015;173(2):G1-G20.

3. Gafni RI, et al. N Engl J Med. 2019;380(18):1738-1747.

4. Mannstadt M, et al. Nat Rev Dis Primers. 2017;3:17055.

5.Hadker N, et al. Endocr Pract. 2014;20(7):671–679.

6. Powers J, et al. J Bone Miner Res. 2013;28(12):2570–2576.

7. Mitchell DM, et al. J Clin Endocrinol Metab. 2012;97(12):4507–4514.

8. Underbjerg L, et al. J Bone Miner Res. 2013;28(11):2277–2285.